AbbVie’s patent-aggressive US strategy for flagship Humira pays off, as judge dismisses lawsuit alleging anticompetitive activity
AbbVie has long fiercely protected its flagship Humira — the world’s bestselling drug — with a patent raincoat perhaps as durable as a Mackintosh. And while it has made a series of moves for a post-Humira future, notably the $63 billion acquisition of Allergan, a US judge has ruled in favor of the company against allegations that it engaged in anticompetitive conduct to elbow out rivals in the United States.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters